Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.31 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.31 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17640888 | 0.90 | TSHR (0.48) | HSD17B10TSHRHTTMAPTMEN1 | |
| SCHEMBL26739892 | 0.89 | ALDH1A1 (0.38) | HSD17B10TDP1TSHRHTTALDH1A1 | |
| SCHEMBL10431252 | 0.87 | CYP3A4 (0.43) | HSD17B10TDP1TSHRHTTALDH1A1 | |
| SCHEMBL18510353 | 0.86 | HTT (0.50) | TDP1TSHRHTTALDH1A1MAPT | |
| SCHEMBL18510364 | 0.86 | HTT (0.50) | TDP1TSHRHTTALDH1A1MAPT | |
| SCHEMBL4497163 | 0.86 | HTT (0.50) | TDP1TSHRHTTALDH1A1MAPT | |
| SCHEMBL18510370 | 0.86 | HTT (0.50) | TDP1TSHRHTTALDH1A1MAPT | |
| SCHEMBL26198723 | 0.86 | HTT (0.50) | TDP1TSHRHTTALDH1A1MAPT | |
| SCHEMBL18510368 | 0.86 | HTT (0.50) | TDP1TSHRHTTALDH1A1MAPT | |
| SCHEMBL15761345 | 0.85 | TSHR (0.48) | TSHRHTTMAPTUSP2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702429-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702429-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | HSD17B10 2781/4885TDP1 3445/4885TSHR 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.